Supplemental Digital Content 1: Flowchart of patients in endpoint analyses

Patients enrolled (n = 574)

More than one visit (n = 322)

No HGAIN
Histology = negative† or AIN1
OR if no histology available, then
  o negative‡ anal cytology; or
  o visually normal HRA.
(n = 152)*

Followed by
HGAIN
Histology = AIN2 or AIN3
OR
Cytology = HSIL
(n = 101)*

Followed by
HGAIN
Histology = AIN2 or AIN3
OR
Cytology = HSIL
(n = 101)*

Histology = AIN3
(n = 55)*

No AIN3
Histology = negative† or AIN1 or AIN2
OR if no histology available, then
  o negative‡ anal cytology; or
  o visually normal HRA.
(n = 199)*

Followed by
No AIN3
Histology = negative† or AIN1 or AIN2
OR if no histology available, then
  o negative‡ anal cytology; or
  o visually normal HRA.
(n = 35)

Histology = AIN3
(n = 25)

Spontaneous regression (n = 24)
  • to histology = AIN1 (n = 17)
  • to histology = negative for AIN (n = 7)

Censored (n= 7)
  • Surgical excision (n= 6)
  • Topical imiquimod (n= 1)

Censored (n= 9)
  • Surgical excision (n= 8)
  • Topical imiquimod (n= 1)

Spontaneous regression (n = 26)
  • to histology = AIN2 (n = 11)
  • to histology = AIN1 (n = 11)
  • to histology = negative for AIN (n = 4)

Analyses using the composite endpoint of HGAIN marked by grey background. Analyses using histologically-confirmed AIN3 endpoint marked by checked background. Analyses of progression are outlined in black. Analyses of regression are outlined in red.

*These groups are not mutually exclusive. †Negative for AIN. ‡Negative for intraepithelial lesion or malignancy.
Abbreviations: AIN1/2/3 = anal intraepithelial neoplasia grade 1/2/3; HGAIN = high-grade anal intraepithelial neoplasia; HRA = high-resolution anoscopy; HSIL = high-grade squamous intraepithelial lesion.